Q3 Earnings Forecast for Illumina Issued By Leerink Partnrs

Illumina, Inc. (NASDAQ:ILMN - Free Report) - Equities research analysts at Leerink Partnrs decreased their Q3 2025 earnings per share (EPS) estimates for Illumina in a note issued to investors on Thursday, April 17th. Leerink Partnrs analyst P. Souda now forecasts that the life sciences company will post earnings per share of $1.05 for the quarter, down from their previous forecast of $1.10. The consensus estimate for Illumina's current full-year earnings is $4.51 per share. Leerink Partnrs also issued estimates for Illumina's Q1 2026 earnings at $1.03 EPS, Q2 2026 earnings at $1.17 EPS, Q3 2026 earnings at $1.30 EPS, Q4 2026 earnings at $1.47 EPS and FY2026 earnings at $4.97 EPS.

Several other analysts have also recently commented on ILMN. Canaccord Genuity Group lowered their target price on Illumina from $135.00 to $115.00 and set a "hold" rating on the stock in a research report on Tuesday, March 11th. Barclays lowered their price objective on shares of Illumina from $100.00 to $77.00 and set an "underweight" rating on the stock in a research note on Thursday, April 10th. Citigroup reduced their target price on Illumina from $90.00 to $85.00 and set a "neutral" rating for the company in a report on Monday, April 7th. Royal Bank of Canada reduced their price objective on shares of Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a research note on Tuesday, April 8th. Finally, Piper Sandler lifted their target price on shares of Illumina from $185.00 to $190.00 and gave the stock an "overweight" rating in a research report on Monday, February 10th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $138.70.

Illumina Stock Performance

Shares of ILMN traded down $2.32 during midday trading on Friday, hitting $71.21. 2,639,652 shares of the stock traded hands, compared to its average volume of 2,274,954. The business's 50 day moving average price is $84.61 and its two-hundred day moving average price is $120.16. The firm has a market capitalization of $11.27 billion, a PE ratio of -9.27, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. Illumina has a 1-year low of $68.70 and a 1-year high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%.

Hedge Funds Weigh In On Illumina

Institutional investors have recently modified their holdings of the stock. Golden State Wealth Management LLC bought a new position in Illumina in the 4th quarter worth approximately $32,000. Versant Capital Management Inc raised its position in shares of Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock worth $32,000 after acquiring an additional 146 shares during the last quarter. Fourth Dimension Wealth LLC acquired a new position in shares of Illumina during the fourth quarter valued at $40,000. Bank Julius Baer & Co. Ltd Zurich bought a new position in Illumina in the fourth quarter valued at about $45,000. Finally, Assetmark Inc. increased its position in Illumina by 954.8% in the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after purchasing an additional 296 shares during the period. 89.42% of the stock is owned by institutional investors.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.